Symptoms Clusters in Oncology Patients Receiving Chemotherapy

$1,031,035R01FY2013CANIH

University Of California, San Francisco, San Francisco CA

Investigators

Christine A. Miaskowskicontact Bradley E Aouizerat

Linked publications & trials

Paper 39377555 Paper 39325169 Paper 38676932 Paper 38532105 Paper 38528755 Paper 38400684 Paper 38365584 Paper 38259094 Paper 38259059 Paper 37354746 Paper 37265072 Paper 37104681 Paper 37084242 Paper 36929768 Paper 36584234 Paper 36470166 Paper 36446517 Paper 36423801 Paper 36373573 Paper 36355215 Paper 36115520 Paper 36076314 Paper 36066629 Paper 35929442 Paper 35688433 Paper 35671438 Paper 35671412 Paper 35569331 Paper 35543816 Paper 35439202 Paper 35397404 Paper 34560709 Paper 34333099 Paper 34298161 Paper 34249477 Paper 34218321 Paper 34183521 Paper 34183520 Paper 34049967 Paper 33454824 Paper 33259906 Paper 32918132 Paper 32835999 Paper 32721501 Paper 32154960 Paper 31956947 Paper 31923555 Paper 31689477 Paper 31428931 Paper 31404646 Paper 31358253 Paper 31349034 Paper 31077784 Paper 30783135 Paper 30768960 Paper 30322507 Paper 30024437 Paper 29706088 Paper 29679368 Paper 29479128 Paper 29279099 Paper 29051114 Paper 28944404 Paper 28859882 Paper 28859255 Paper 28838866 Paper 28825498 Paper 28716620 Paper 28533161 Paper 28478849 Paper 28281049 Paper 28280616 Paper 28110208 Paper 28063861 Paper 27766422 Paper 27649058 Paper 27456383 Paper 26975624 Paper 26957308 Paper 26895413 Paper 26777053 Paper 26683234 Paper 26361758 Paper 26142303 Paper 25828560 Paper 25828559 Paper 24797450 Paper 22542321 Paper 22393192

Abstract

DESCRIPTION (provided by applicant): Symptom cluster research is an emerging area in the field of oncology symptom management. While an increase in knowledge about symptom clusters has occurred in the past seven years, a number of outstanding issues and questions remain. The overall goal of this grant application is to further our understanding of the occurrence and effects of symptom clusters in oncology patients. Specifically, this study will address two important aspects of symptom cluster research, namely 1) the identification of symptom clusters in oncology outpatients who are receiving chemotherapy (CTX) AND 2) the identification of subgroups of oncology outpatients based on their experience with four highly prevalent symptoms (i.e., pain, fatigue, sleep disturbance, and depression). Based on five preliminary studies, we will attempt to identify the genomic markers for the different patient subgroups identified in part 2 of this study. Patients (n=1786 to have a final sample of 1500) with breast, lung, colon, and ovarian cancer who will receive their second or third cycle of CTX will be enrolled in this longitudinal study. Patients will complete self-report questionnaires a total of six times over 2 cycles of CTX to evaluate for the number and types of symptom clusters and for changes in symptom clusters over time. In addition, cluster analysis procedures will be employed to create subgroups of patients based on their experience with the symptoms of pain, fatigue, sleep disturbance and depression. Based on our previous research we anticipate that two subgroups of patients will be identified (i.e., patients who experience high level of all four symptoms (~10. percent of the sample) and patients who experience low levels of all four symptoms (4.3 percent of the sample). A two stage genome wide association study will be done with the DNA from these two subgroups to identify genomic markers for these two distinct groups of patients.

View original record on NIH RePORTER →